Table 4.
Statistical influential variables
| Variable | P-value (infections vs. No infection) | Odds ratio (95%CI) |
|---|---|---|
|
Gender |
0,43 |
0,76 (0.39-1.49) |
|
Age (≤60,<60 years) |
0,69 |
1.15 (0.57-2.35) |
|
Stage |
0,076 |
n.a |
|
Number of prior therapies |
0,015* |
n.a. |
|
Number of doses of Rituximab |
0,35 |
n.a. |
|
Chemotherapy in addition to Rituximab |
0,006* |
n.a. |
|
Asplenia |
0,45 |
0.56 (0.12-2.58) |
|
Active malignancy at start of therapy
§
|
0,007* |
6.75 (1.4-32.5)* |
|
Active malignancy at end of therapy |
0,02* |
3.06 (1.14-8.17)* |
|
Application of G-CSF |
0,013*# |
2.38 (1.19-4.76) |
|
Cotrimoxazole prophylaxis |
0,0001*# |
5.64 (2.51-12.64) |
|
HIB/pneumococci vaccination |
0,09 |
0.18 (0.02-1.66) |
|
Substitution of immunoglobulins |
0,45 |
0.56 (0.12-2.58) |
|
Neutropenia |
0,0001* |
4.86 (2.37-9.99)* |
|
Lymphopenia |
0,045* |
6.96 (0.79-61.26)* |
|
Leukopenia |
0,0001* |
4.51 (2.09-9.74)* |
| Relevant comorbidities | 0,63 | 1.16 (0.54-2.49) |
*statistically significant in univariate analysis.
n.a.: not applicable.
§ as patients with maintenance therapy and nonmalignant disorders had been treated with Rituximab not all patients had active malignancy at start of therapy.
#Paradoxically, patients with infectious complications had significantly more often been treated with G-CSF and received Cotrimoxazole prophylaxis, probably as these antiinfective measures had been administered to patients receiving more intensive chemotherapeutic regimens (such as GMALL, or R-CHOEP).